Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Arkema (AKE.PA)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (€)	Price Target (€)	Rating
2022-02-11	128.70	128.00	Neutral
2022-07-14	84.02	82.00	Sell
2022-08-08	92.86	85.00	Sell
2022-10-11	72.38	72.00	Sell
2022-11-16	86.16	78.00	Sell
2023-01-20	92.36	80.00	Sell
2023-03-06	98.22	105.00	Neutral
2023-04-13	89.06	98.00	Neutral
2023-08-01	96.28	102.00	Neutral
2023-10-12	90.36	95.00	Neutral
2023-12-13	96.38	120.00	Buy
2024-07-03	85.50	125.00	Buy
2024-08-08	78.55	115.00	Buy
2024-10-14	84.35	105.00	Buy
2025-03-14	82.65	100.00	Buy

Disclosures

UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.